120 related articles for article (PubMed ID: 16969334)
1. [PET in thyroid cancers].
Talbot JN; Montravers F; Younsi N; Zanotti-Fregonara P; Grahek D; Kerrou K; Gutman F; Périé S; Maurel G; Saint Guily JL; Devaux JY; Duron F
Presse Med; 2006 Sep; 35(9 Pt 2):1377-85. PubMed ID: 16969334
[TBL] [Abstract][Full Text] [Related]
2. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer.
Chen SW; Chen YK
World J Surg Oncol; 2017 Dec; 15(1):230. PubMed ID: 29284496
[TBL] [Abstract][Full Text] [Related]
3. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
Frilling A; Tecklenborg K; Görges R; Weber F; Clausen M; Broelsch EC
Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
[TBL] [Abstract][Full Text] [Related]
4. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
5. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
Lind P; Kohlfürst S
Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
Mucha SA; Kunert-Radek J; Pomorski L
Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852
[TBL] [Abstract][Full Text] [Related]
7. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
[TBL] [Abstract][Full Text] [Related]
8. Utility of 8F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody.
Kingpetch K; Pipatrattana R; Tepmongkol S; Sirisalipoch S; Chaiwatanarat T
J Med Assoc Thai; 2011 Oct; 94(10):1238-44. PubMed ID: 22145510
[TBL] [Abstract][Full Text] [Related]
9. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels.
Muros MA; Llamas-Elvira JM; Ramírez-Navarro A; Gómez MJ; Rodríguez-Fernández A; Muros T; López de la Torre M; Becerra A; Carreras JL
Am J Surg; 2000 Jun; 179(6):457-61. PubMed ID: 11004330
[TBL] [Abstract][Full Text] [Related]
10. F-18 FDG PET detection of a medullary thyroid carcinoma in a patient with metastatic colonic cancer; literature review.
Cohen R; Bihan H; des Guetz G; Wind P; Martin A
Ann Endocrinol (Paris); 2009 Dec; 70(6):468-72. PubMed ID: 19744643
[TBL] [Abstract][Full Text] [Related]
11. Review. 18F-FDG PET in the diagnosis and follow-up of thyroid malignancy.
Al-Nahhas A; Khan S; Gogbashian A; Banti E; Rampin L; Rubello D
In Vivo; 2008; 22(1):109-14. PubMed ID: 18396792
[TBL] [Abstract][Full Text] [Related]
12. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
13. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging.
Marzola MC; Pelizzo MR; Ferdeghini M; Toniato A; Massaro A; Ambrosini V; Fanti S; Gross MD; Al-Nahhas A; Rubello D
Eur J Surg Oncol; 2010 Apr; 36(4):414-21. PubMed ID: 20100647
[TBL] [Abstract][Full Text] [Related]
14. Localization of medullary thyroid carcinoma after surgery using (11)C-methionine PET/CT: comparison with (18)F-FDG PET/CT.
Jang HW; Choi JY; Lee JI; Kim HK; Shin HW; Shin JH; Kim SW; Chung JH
Endocr J; 2010; 57(12):1045-54. PubMed ID: 20978365
[TBL] [Abstract][Full Text] [Related]
15. Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer.
Nanni C; Rubello D; Fanti S; Farsad M; Ambrosini V; Rampin L; Banti E; Carpi A; Muzzio P; Franchi R
Biomed Pharmacother; 2006 Sep; 60(8):409-13. PubMed ID: 16891093
[TBL] [Abstract][Full Text] [Related]
16. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
[TBL] [Abstract][Full Text] [Related]
17. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
Dennis K; Hay JH; Wilson DC
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
[TBL] [Abstract][Full Text] [Related]
18. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer.
de Groot JW; Links TP; Jager PL; Kahraman T; Plukker JT
Ann Surg Oncol; 2004 Aug; 11(8):786-94. PubMed ID: 15289241
[TBL] [Abstract][Full Text] [Related]
19. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
Shiga T; Tsukamoto E; Nakada K; Morita K; Kato T; Mabuchi M; Yoshinaga K; Katoh C; Kuge Y; Tamaki N
J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516
[TBL] [Abstract][Full Text] [Related]
20. PET imaging in differentiated thyroid cancer: where does it fit and how do we use it?
Hall NC; Kloos RT
Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):793-805. PubMed ID: 17891243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
